fragile X messenger ribonucleoprotein 1 (Ensembl:FMRP translational regulator 1)
RGD ID:
2623
Description:
Enables several functions, including RNA binding activity; enzyme binding activity; and translation regulator activity. Involved in several processes, including modulation of chemical synaptic transmission; negative regulation of transport; and regulation of protein metabolic process. Located in several cellular components, including cytoplasmic ribonucleoprotein granule; dendrite; and distal axon. Part of polysome. Is active in Schaffer collateral - CA1 synapse; glutamatergic synapse; and postsynaptic cytosol. Used to study autism spectrum disorder and fragile X syndrome. Biomarker of myoclonic-atonic epilepsy; transient cerebral ischemia; and withdrawal disorder. Human ortholog(s) of this gene implicated in fragile X syndrome; fragile X-associated tremor/ataxia syndrome; and primary ovarian insufficiency 1. Orthologous to human FMR1 (fragile X messenger ribonucleoprotein 1); INTERACTS WITH (S)-3,5-dihydroxyphenylglycine; 2,3,7,8-tetrachlorodibenzodioxine; 2,4-dinitrotoluene.
acamprosate inhibits the reaction [FMR1 protein affects the phosphorylation of MAPK1 protein], acamprosate inhibits the reaction [FMR1 protein affects the phosphorylation of MAPK3 protein]
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMR1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMR1 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FMR1 mRNA
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [FMR1 5' UTR mutant form results in increased abundance of Hydroxyl Radical], Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [FMR1 5' UTR mutant form results in increased abundance of Superoxides]
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMR1 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FMR1 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FMR1 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FMR1 mRNA
[Toluene co-treated with Xylenes co-treated with ethylbenzene] results in decreased expression of FMR1 mRNA, [Toluene co-treated with Xylenes co-treated with ethylbenzene] results in increased methylation of FMR1 gene
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FMR1 mRNA
6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Potassium Chloride affects the localization of FMR1 protein], methyl-(4-carboxyphenyl)glycine inhibits the reaction [Potassium Chloride affects the localization of FMR1 protein]
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FMR1 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FMR1 mRNA
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of FMR1 mRNA
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FMR1 mRNA
Metabotropic glutamate receptor activation regulates fragile x mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses.
The nuclear microspherule protein 58 is a novel RNA-binding protein that interacts with fragile X mental retardation protein in polyribosomal mRNPs from neurons.
Translational regulation of NeuroD1 expression by FMRP: involvement in glutamatergic neuronal differentiation of cultured rat primary neural progenitor cells.
Fragile X mental retardation protein shifts between polyribosomes and stress granules after neuronal injury by arsenite stress or in vivo hippocampal electrode insertion.
The RNA binding and transport proteins staufen and fragile X mental retardation protein are expressed by rat primary afferent neurons and localize to peripheral and central axons.